Cancer Treatment Methods Using Tumor Treating Fields, Chemotherapy, and Anti-Fibrotic Agents
Summary
The USPTO has published a patent application detailing methods for treating cancer. The application describes compositions and systems involving the concurrent application of tumor treating fields, chemotherapeutic agents, and anti-fibrotic agents to reduce cancer cell viability and tumor growth.
What changed
This document is a published patent application (US20260083726A1) from the USPTO, detailing novel methods for cancer treatment. The core innovation involves the combined application of alternating tumor treating fields with chemotherapeutic and anti-fibrotic agents. The abstract specifies that these methods aim to reduce cancer cell viability, treat cancer, and prevent tumor volume increase.
While this is a patent application and not a regulatory rule, it signifies potential future developments in cancer therapy. Companies involved in pharmaceutical development, medical device manufacturing, and healthcare providers should be aware of this technological advancement. No immediate compliance actions are required, but it may influence future research, development, and treatment protocols in oncology.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS, CHEMOTHERAPEUTIC AGENTS, AND ANTI-FIBROTIC AGENTS
Application US20260083726A1 Kind: A1 Mar 26, 2026
Inventors
Gitit LAVY-SHAHAF, Tali Voloshin-Sela, Lilach Avigdor
Abstract
Compositions, systems, and methods for reducing viability of cancer cells and treating cancer, as well as preventing an increase of volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating field concurrently with administration of at least one chemotherapeutic agent and at least one anti-fibrotic agent.
CPC Classifications
A61K 31/495 A61K 31/337 A61K 31/4178 A61K 31/436 A61K 31/47 A61K 31/496 A61K 31/505 A61K 31/506 A61K 31/5377 A61K 31/704 A61K 31/7048 A61K 33/243 A61P 35/00 A61N 1/36002
Filing Date
2025-09-22
Application No.
19335499
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.